BioCentury
ARTICLE | Company News

GamaMabs Pharma, Laboratoire francais deal

October 7, 2013 7:00 AM UTC

LFB granted newco GamaMabs an exclusive, worldwide license to 3C23K, a mAb against anti-Mullerian hormone receptor type II (AMHR2) that is in development to treat gynecological cancers, including ov...